Do analysts rate CDT or BCAB?

BioAtla has a consensus target price of $200.00, indicating a potential upside of 4,912.53%. Given BioAtla's stronger consensus rating and higher possible upside, analysts plainly believe BioAtla is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, CDT or BCAB?

CDT Equity has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A BioAtla $2M 3.31 -$59.61M -$41.72 N/A

Is CDT or BCAB more profitable?

BioAtla's return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -4,263.33% -529.91% BioAtla N/A N/A -325.64%

Do analysts rate PBM or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, PBM or CDT?

CDT Equity is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Psyence Biomedical N/A N/A -$6.94M $25.34 0.12 CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is PBM or CDT more profitable?

Psyence Biomedical's return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Psyence Biomedical N/A N/A N/A CDT Equity N/A -4,263.33% -529.91%

Does the media favor PBM or CDT?

In the previous week, CDT Equity had 3 more articles in the media than Psyence Biomedical. MarketBeat recorded 5 mentions for CDT Equity and 2 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.27 beat CDT Equity's score of 0.49 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CDT Equity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ENTO or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, ENTO or CDT?

Entero Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is ENTO or CDT more profitable?

Entero Therapeutics' return on equity of -461.02% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -461.02% -14.72% CDT Equity N/A -4,263.33% -529.91%

Do analysts recommend PCSA or CDT?

Heatwurx presently has a consensus price target of $25.00, suggesting a potential upside of 1,016.07%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts clearly believe Heatwurx is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PCSA or CDT?

Heatwurx is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$9.29 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is PCSA or CDT more profitable?

Heatwurx's return on equity of -281.31% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% CDT Equity N/A -4,263.33% -529.91%

Do analysts recommend TNFA or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, TNFA or CDT?

TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is TNFA or CDT more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets TNF Pharmaceuticals N/A -69.21% -33.98% CDT Equity N/A -4,263.33% -529.91%

CDT Equity (CDT) Competitors

$0.36 +0.00 (+1.14%)

Closing price 04:00 PM Eastern

Extended Trading

$0.35 -0.01 (-1.97%)

As of 07:59 PM Eastern

Compare

CDT vs. BCAB, PBM, ENTO, PCSA, and TNFA

Should you buy CDT Equity stock or one of its competitors? MarketBeat compares CDT Equity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CDT Equity include BioAtla (BCAB), Psyence Biomedical (PBM), Entero Therapeutics (ENTO), Heatwurx (PCSA), and TNF Pharmaceuticals (TNFA). These companies are all part of the "pharmaceutical products" industry.

How does CDT Equity compare to BioAtla?

CDT Equity (NASDAQ:CDT) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 10.8% of CDT Equity shares are owned by company insiders. Comparatively, 9.3% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, CDT Equity had 4 more articles in the media than BioAtla. MarketBeat recorded 5 mentions for CDT Equity and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat CDT Equity's score of 0.49 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
CDT Equity	Neutral
BioAtla	Very Positive

BioAtla's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
BioAtla	N/A	N/A	-325.64%

CDT Equity has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
BioAtla	$2M	3.31	-$59.61M	-$41.72	N/A

CDT Equity has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

BioAtla has a consensus target price of $200.00, indicating a potential upside of 4,912.53%. Given BioAtla's stronger consensus rating and higher possible upside, analysts plainly believe BioAtla is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioAtla beats CDT Equity on 9 of the 14 factors compared between the two stocks.

How does CDT Equity compare to Psyence Biomedical?

Psyence Biomedical (NASDAQ:PBM) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Psyence Biomedical's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
CDT Equity	N/A	-4,263.33%	-529.91%

CDT Equity is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	-$6.94M	$25.34	0.12
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Psyence Biomedical has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, CDT Equity had 3 more articles in the media than Psyence Biomedical. MarketBeat recorded 5 mentions for CDT Equity and 2 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.27 beat CDT Equity's score of 0.49 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDT Equity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Psyence Biomedical beats CDT Equity on 8 of the 10 factors compared between the two stocks.

How does CDT Equity compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:ENTO) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

In the previous week, CDT Equity had 5 more articles in the media than Entero Therapeutics. MarketBeat recorded 5 mentions for CDT Equity and 0 mentions for Entero Therapeutics. CDT Equity's average media sentiment score of 0.49 beat Entero Therapeutics' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Entero Therapeutics	Neutral
CDT Equity	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Entero Therapeutics' return on equity of -461.02% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
CDT Equity	N/A	-4,263.33%	-529.91%

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 10.8% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Entero Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Entero Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Summary

Entero Therapeutics and CDT Equity tied by winning 5 of the 10 factors compared between the two stocks.

How does CDT Equity compare to Heatwurx?

Heatwurx (NASDAQ:PCSA) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Heatwurx has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Heatwurx presently has a consensus price target of $25.00, suggesting a potential upside of 1,016.07%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts clearly believe Heatwurx is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CDT Equity had 4 more articles in the media than Heatwurx. MarketBeat recorded 5 mentions for CDT Equity and 1 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.87 beat CDT Equity's score of 0.49 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Very Positive
CDT Equity	Neutral

Heatwurx is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Heatwurx's return on equity of -281.31% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
CDT Equity	N/A	-4,263.33%	-529.91%

Summary

Heatwurx beats CDT Equity on 9 of the 13 factors compared between the two stocks.

How does CDT Equity compare to TNF Pharmaceuticals?

TNF Pharmaceuticals (NASDAQ:TNFA) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

TNF Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

In the previous week, CDT Equity had 5 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 5 mentions for CDT Equity and 0 mentions for TNF Pharmaceuticals. CDT Equity's average media sentiment score of 0.49 beat TNF Pharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
TNF Pharmaceuticals	Neutral
CDT Equity	Neutral

9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

TNF Pharmaceuticals' return on equity of -69.21% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
CDT Equity	N/A	-4,263.33%	-529.91%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TNF Pharmaceuticals beats CDT Equity on 6 of the 10 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDT vs. The Competition

Export

Metric	CDT Equity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71M	$3.03B	$6.96B	$12.67B
Dividend Yield	N/A	2.09%	2.68%	8.87%
P/E Ratio	0.00	19.86	27.21	24.05
Price / Sales	N/A	343.53	519.51	89.73
Price / Cash	N/A	56.84	49.25	59.89
Price / Book	0.00	4.23	10.78	6.23
Net Income	-$39.22M	$65.46M	$3.59B	$331.94M
7 Day Performance	-13.41%	-3.99%	-2.55%	-1.93%
1 Month Performance	-50.54%	1.63%	2.81%	-0.97%
1 Year Performance	-99.92%	17.90%	25.42%	18.24%

CDT Equity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDT CDT Equity	0.4501 of 5 stars	$0.36 +1.1%	N/A	-99.9%	$1.71M	N/A	N/A	3	Earnings Report Gap Down
BCAB BioAtla	2.4594 of 5 stars	$4.06 +3.8%	$200.00 +4,826.1%	-78.4%	$6.74M	$2M	N/A	60	Positive News
PBM Psyence Biomedical	1.3353 of 5 stars	$2.87 +0.7%	N/A	-91.2%	$6.57M	N/A	0.11	N/A	Positive News Gap Up
ENTO Entero Therapeutics	0.017 of 5 stars	$4.07 -9.6%	N/A	+172.3%	$6.46M	N/A	N/A	9
PCSA Heatwurx	4.0543 of 5 stars	$2.29 +11.2%	$25.00 +991.7%	-53.5%	$6.34M	N/A	N/A	20	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDT) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CDT Equity (CDT) Competitors

CDT vs. BCAB, PBM, ENTO, PCSA, and TNFA

How does CDT Equity compare to BioAtla?

Summary

How does CDT Equity compare to Psyence Biomedical?

Summary

How does CDT Equity compare to Entero Therapeutics?

Summary

How does CDT Equity compare to Heatwurx?

Summary

How does CDT Equity compare to TNF Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CDT Equity (CDT) Competitors

CDT vs. BCAB, PBM, ENTO, PCSA, and TNFA

How does CDT Equity compare to BioAtla?

Do institutionals and insiders believe in CDT or BCAB?

Does the media favor CDT or BCAB?

Is CDT or BCAB more profitable?

Which has higher earnings & valuation, CDT or BCAB?

Which has more volatility & risk, CDT or BCAB?

Do analysts rate CDT or BCAB?

Summary

How does CDT Equity compare to Psyence Biomedical?

Is PBM or CDT more profitable?

Which has preferable valuation & earnings, PBM or CDT?

Which has more risk and volatility, PBM or CDT?

Do insiders and institutionals believe in PBM or CDT?

Do analysts rate PBM or CDT?

Does the media favor PBM or CDT?

Summary

How does CDT Equity compare to Entero Therapeutics?

Does the media refer more to ENTO or CDT?

Do analysts recommend ENTO or CDT?

Is ENTO or CDT more profitable?

Do institutionals & insiders believe in ENTO or CDT?

Which has higher valuation & earnings, ENTO or CDT?

Which has more volatility and risk, ENTO or CDT?

Summary

How does CDT Equity compare to Heatwurx?

Which has more volatility & risk, PCSA or CDT?

Do analysts recommend PCSA or CDT?

Do institutionals and insiders hold more shares of PCSA or CDT?

Does the media refer more to PCSA or CDT?

Which has stronger earnings & valuation, PCSA or CDT?

Is PCSA or CDT more profitable?

Summary

How does CDT Equity compare to TNF Pharmaceuticals?

Which has more volatility and risk, TNFA or CDT?

Does the media favor TNFA or CDT?

Do insiders & institutionals believe in TNFA or CDT?

Which has stronger valuation and earnings, TNFA or CDT?

Is TNFA or CDT more profitable?

Do analysts recommend TNFA or CDT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools